A new survey of health economics and outcomes research (HEOR) leaders in pharmaceutical companies found a high level of confidence that the industry will continue to invest in such research, says a study from Center for the Evaluation of Value and Risk in Health. Ninety-two percent of respondents said they think HEOR will be used more frequently by their companies in the future. In addition, 55 percent said FDAMA Section 114 has been a useful channel for promotion of health economics information, and 49 percent said the U.S. government should use cost-effectiveness analysis in coverage and reimbursement decisions. More information here. (Source: Expert Reviews, 2013).